Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Dermatomyositis is a rare inflammatory disease that is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.
The Dermatomyositis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects.
Dermatomyositis Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Dermatomyositis pipeline drugs market are Complement C5, Interferon Beta, Non Receptor Tyrosine Protein Kinase TYK2, Proteasome Subunit Beta Type 8, C-X-C Chemokine Receptor Type 4, CD8, and others.
Dermatomyositis Pipeline Drugs Market Analysis, by Targets
For more Dermatomyositis pipeline drugs market target insights, download a free report sample
Dermatomyositis Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Dermatomyositis pipeline drugs market are Complement C5 Inhibitor, Interferon Beta Inhibitor, Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor, Proteasome Subunit Beta Type 8 Inhibitor, C-X-C Chemokine Receptor Type 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, and others.
Dermatomyositis Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the Dermatomyositis pipeline drugs market, download a free report sample
Dermatomyositis Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Dermatomyositis pipeline drugs market are intravenous, subcutaneous, oral, inhalational, intravenous bolus, and others.
Dermatomyositis Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Dermatomyositis pipeline drugs market, download a free report sample
Dermatomyositis Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Dermatomyositis pipeline drugs market are Small Molecule, Monoclonal Antibody, Biologic, Gene-Modified Cell Therapy, Antibody, Blood Derivative, and others.
Dermatomyositis Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Dermatomyositis pipeline drugs market, download a free report sample
Dermatomyositis Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Dermatomyositis pipeline drugs market are Pfizer Inc, Alexion Pharmaceuticals Inc, Kezar Life Sciences Inc, Adienne Pharma & Biotech SA, Argenx SE, Avotres Inc, and others.
Dermatomyositis Pipeline Drugs Market Analysis, by Companies
To know more about the Dermatomyositis pipeline drugs market companies, download a free report sample
Dermatomyositis Pipeline Drugs Market Report Overview
| Key Targets | Complement C5, Interferon Beta, Non Receptor Tyrosine Protein Kinase TYK2, Proteasome Subunit Beta Type 8, C-X-C Chemokine Receptor Type 4, CD8, and others |
| Key Mechanism of Actions | Complement C5 Inhibitor, Interferon Beta Inhibitor, Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor, Proteasome Subunit Beta Type 8 Inhibitor, C-X-C Chemokine Receptor Type 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, and others |
| Key Routes of Administration | Intravenous, Subcutaneous, Oral, Inhalational, Intravenous Bolus, and others |
| Key Molecule Types | Small Molecule, Monoclonal Antibody, Biologic, Gene-Modified Cell Therapy, Antibody, Blood Derivative, and others |
| Key Companies | Pfizer Inc, Alexion Pharmaceuticals Inc, Kezar Life Sciences Inc, Adienne Pharma & Biotech SA, Argenx SE, Avotres Inc, and others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis.
- The pipeline guide reviews pipeline therapeutics for Dermatomyositis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dermatomyositis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dermatomyositis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Dermatomyositis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dermatomyositis.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Dermatomyositis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Alexion Pharmaceuticals Inc
Argenx SE
Avotres Inc
Cellular Biomedicine Group Ltd
CSL Ltd
Ermium Therapeutics SAS
Fresh Tracks Therapeutics Inc
Galapagos NV
GNI Group Ltd
Horizon Therapeutics Plc
Juventas Cell Therapy Ltd
Kezar Life Sciences Inc
NovelMed Therapeutics Inc
Paean Biotechnology Inc
Pfizer Inc
Priovant Therapeutics Inc
Santhera Pharmaceuticals Holding AG
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Dermatomyositis pipeline drugs market?
Some of the targets of the Dermatomyositis pipeline drugs market are Complement C5, Interferon Beta, Non Receptor Tyrosine Protein Kinase TYK2, Proteasome Subunit Beta Type 8, C-X-C Chemokine Receptor Type 4, CD8, and others.
-
What are the key mechanisms of action in the Dermatomyositis pipeline drugs market?
Some of the mechanisms of action of the Dermatomyositis pipeline drugs market are Complement C5 Inhibitor, Interferon Beta Inhibitor, Non Receptor Tyrosine Protein Kinase TYK2 Inhibitor, Proteasome Subunit Beta Type 8 Inhibitor, C-X-C Chemokine Receptor Type 4 Antagonist, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, and others.
-
What are the key routes of administration in the Dermatomyositis pipeline drugs market?
The key routes of administration in the Dermatomyositis pipeline drugs market are intravenous, subcutaneous, oral, inhalational, intravenous bolus, and others.
-
What are the key molecule types in the Dermatomyositis pipeline drugs market?
The molecule types in the Dermatomyositis pipeline drugs market are Small Molecule, Monoclonal Antibody, Biologic, Gene-Modified Cell Therapy, Antibody, Blood Derivative, and others.
-
Which are the leading companies in the Dermatomyositis pipeline drugs market?
Some of the leading companies in the Dermatomyositis pipeline drugs market are Pfizer Inc, Alexion Pharmaceuticals Inc, Kezar Life Sciences Inc, Adienne Pharma & Biotech SA, Argenx SE, Avotres Inc, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Musculoskeletal Disorders reports